Skip to main content

Table 1 Characteristics of the study cohorts

From: Immune correlates of cardiovascular co-morbidity in HIV infected participants from South India

Demographic characteristics

Group 1 (n = 102)

Group 2 (n = 172)

Group 3 (n = 64)

p-value Group 1 vs 2

p-value Group 1 vs 3

p-value Group 2 vs 3

Group 1a (n = 29)

Group 1b (n = 22)

Group 1c (n = 51)

p-value Group 1a vs 1b

p-value Group 1a vs 1c

p-value Group 1b vs 1c

Group 2a (n = 51)

Group 2b (n = 51)

Group 2c (n = 70)

p-value Group 2a vs 2b

p-value Group 2a vs 2c

p-value Group 2b vs 2c

Age (in years)

36.5 ± 5.8

38.6 ± 5.9

36.8 ± 7.09

0.068

0.795

0.07

37.90 ± 6.28

36.82 ± 6.09

35.71 ± 5.41

0.542

0.105

0.441

38.82 ± 5.48

38.10 ± 6.17

38.94 ± 6.17

0.532

0.913

0.459

Gender (M/F)

50/52

114/58

18/46

   

17/12

15/7

18/33

   

35/16

35/16

44/26

   

Known period of infection (in months)

15 (2, 42)

72 (39.5, 92)

–

 < 0.001

–

–

2 (1, 19)

2 (1, 3)

35 (16.5, 49)

0.418

0.001

 < 0.001

74 (31, 114.5)

69 (41.5, 90.5)

72 (44, 81)

0.416

0.326

0.929

Nadir CD4 + T-cell count (cells/ mm3)

353 (167, 544)

307 (186.5, 427)

–

0.118

–

–

70.5 (45.5, 119)

281 (238, 314)

544 (454, 631.5)

 < 0.001

 < 0.001

 < 0.001

119 (83, 165.5)

277 (227.5, 313)

450 (392, 540)

 < 0.001

 < 0.001

 < 0.001

CD4 + T-cell count at the time of study entry (cells/ mm3)

352 (167, 581)

722 (560, 935)

–

 < 0.001

–

–

70.5 (45.5, 119)

281 (238, 314)

581 (495, 771.5)

 < 0.001

 < 0.001

 < 0.001

553 (422.5, 731.5)

659 (560, 817.5)

871 (709, 1044)

0.038

 < 0.001

 < 0.001

Duration on ART (in months)

–

43 (22, 72)

–

–

–

–

–

–

–

   

52 (25.5, 85)

32 (19, 50.5)

53 (22, 74)

0.021

0.248

0.068

Body Mass Index (Kg/m2)

22.7 (20.1, 26.3)

22 (19, 25.8)

24.6 (22.5, 27.1)

0.844

0.013

0.006

21.4 (16.85, 23)

22.3 (20.1, 27.2)

24.2 (21.7, 27.3)

0.072

 < 0.001

0.269

24.4 (19.9, 27.8)

23 (19.1, 25.85)

22.4 (19.2, 25.3)

0.133

0.02

0.392

  1. Group 1, ART naïve patients; Group 2, Patients on ART; Group 3, HIV-uninfected controls. Groups 1a and 2a, nadir CD4 + T-cell count < 200 cells/mm3; Groups 1b and 2b, nadir CD4 + T-cell count 200–350 cells/mm3; Groups 1c and 2c, On ART patients with nadir CD4 + T-cell count > 350 cells/mm3. All descriptive variables are provided as median and interquartile ranges except for age, which is provided as mean ± SD. Independent samples T-test was used to calculate p-value between the groups for ‘age’ which was normally distributed, while Mann–Whitney U-test was used for other non-normally distributed variables. Statistically significant values are in bold
Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us